GLAXOSMITHKLINE PLC Form 6-K August 01, 2016

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934

For period ending 01 August 2016

GlaxoSmithKline plc (Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS (Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F

Form 20-F x Form 40-F

--

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes No x

GlaxoSmithKline plc

(the, Company')

Transaction notification

1. Details of PDMR/person closely associated with them

`('PCA')

a) Name Ms C Thomas

b)Position/status

Senior Vice President,
Human Resources

Initial notification/

amendment Initial notification

Details of the issuer, emission allowance market

2. participant, auction platform, auctioneer or auction

monitor

a) Name GlaxoSmithKline plc

b)LEI 5493000HZTVUYLO1D793 Details of the transaction(s): section to be repeated for

3. (i) each type of instrument; (ii) each type of

transaction; (iii) each date; and (iv) each place where

transaction(s) has been conducted

Description

of Ordinary shares of 25 pence the each ('Ordinary Shares') financial ISIN: GB0009252882

instrument

Nature

Of
the
transaction

The exercise of options over
20,180 Ordinary Shares,
granted on 19 February 2008
under the GlaxoSmithKline

Share Option Plan.

Price(s) Price(s) Volume(s)

c) and volume(s) £11.47 20,180

n/a (single transaction)

Aggregated information

d)

Aggregated volume Price

Date of

e) the 2016-07-28

transaction Place

f) the transaction n/a

Details of PDMR/person closely associated with them

('PCA')

a) Name Ms C Thomas

b)Position/status

Senior Vice President,
Human Resources

c) Initial notification/ amendment

Initial notification

Details of the issuer, emission allowance market

2. participant, auction platform, auctioneer or auction

monitor

a) Name GlaxoSmithKline plc

b)LEI 5493000HZTVUYLO1D793 Details of the transaction(s): section to be repeated for

3. (i) each type of instrument; (ii) each type of

transaction; (iii) each date; and (iv) each place where

transaction(s) has been conducted

Description

of Ordinary shares of 25 pence each ('Ordinary Shares')

a) the ISIN: GB0009252882

instrument

Nature

Sale of 17,024 Ordinary

Shares to satisfy option costs

and the tax and NI liability

b) of exercise of options over

the 20,180 Ordinary Shares

granted on 19 February 2008

under the GlaxoSmithKline

Share Option Plan.

Price(s) Price(s) Volume(s)

c) and £17.0778 17.024

volume(s) £17.07/8 17,024

n/a (single transaction)

Aggregated information

d)

Aggregated volume Price

Date of

e) the 2016-07-28

transaction Place

of London Stock Exchange

the transaction (XLON)

Details of PDMR/person closely associated with them

('PCA')

a) Name Ms C Thomas

Senior Vice President, b) Position/status **Human Resources** 

c) Initial notification/amendment Initial notification

Details of the issuer, emission allowance market

2. participant, auction platform, auctioneer or auction

monitor

a) Name GlaxoSmithKline plc

b)LEI 5493000HZTVUYLO1D793 Details of the transaction(s): section to be repeated for

3. (i) each type of instrument; (ii) each type of

transaction; (iii) each date; and (iv) each place where

transaction(s) has been conducted

Description

Ordinary shares of 25 pence of a) the each ('Ordinary Shares') ISIN: GB0009252882

financial

instrument

The exercise of options over Nature 20,180 Ordinary Shares, of b) the granted on 20 February 2007 under the GlaxoSmithKline transaction

Share Option Plan.

Price(s) Price(s) Volume(s)

c) and £14.88

20,180 volume(s)

n/a (single transaction)

Aggregated information

d)

Aggregated volume Price

Date of

2016-07-28 e) the

transaction Place

n/a the transaction

1. Details of PDMR/person closely associated with them ('PCA')

a) Name Ms C Thomas

Senior Vice President, b) Position/status **Human Resources** 

c) Initial notification/

Initial notification amendment

Details of the issuer, emission allowance market 2. participant, auction platform, auctioneer or auction monitor

a) Name GlaxoSmithKline plc

b)LEI 5493000HZTVUYLO1D793 Details of the transaction(s): section to be repeated for

3. (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where

transaction(s) has been conducted

Description Ordinary shares of 25 pence of each ('Ordinary Shares') a) the financial ISIN: GB0009252882

instrument

Sale of 19,235 Ordinary

Shares to satisfy option costs and the tax and NI liability

Nature arising following the of b) the exercise of options over 20,180 Ordinary Shares transaction

granted on 20 February 2007 under the GlaxoSmithKline

Share Option Plan.

Price(s) Price(s) Volume(s) c) and £17.0814 19.235 volume(s)

n/a (single transaction)

Aggregated information

d)

Aggregated volume Price

Date of

2016-07-28 e) the

transaction Place

London Stock Exchange

the transaction (XLON)

#### **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc (Registrant) Date: August 01, 2016

By: VICTORIA WHYTE

-----

Victoria Whyte Authorised Signatory for and on behalf of GlaxoSmithKline plc